“…Its research profile is accumulating, a hallmark for use in legal settings" (Young et al, 2020, p. 9). Although the IOP-29 was published only relatively recently in 2017 (Viglione et al, 2017), all 12 published studies since then support its validity and effectiveness (Gegner et al, 2021;Giromini et al, 2018Giromini et al, , 2020aIlgunaite et al, 2020;Roma et al, 2020;Viglione et al, 2017Viglione et al, , 2019Winters et al, 2020). Specifically, the results of these studies suggest that (a) the validity and classification accuracy of the IOP-29 compares favorably to that of popular measures like the Structured Inventory of Malingered Symptomatology (SIMS; Smith & Burger, 1997) (Giromini et al, 2018) or Rey Fifteen-Item Test (FIT; Lezak, 1995;Rey, 1941) (Gegner et al, 2021); (b) the IOP-29 is similarly valid when addressing feigning of different conditions such as depression, neuropsychological impairment, psychosis and/or PTSD (e.g., Giromini et al, 2020b;Ilgunaite et al, 2020;Winters et al, 2020); (c) the validity of the IOP-29 is maintained both when adopting a simulation/analogue (e.g., Gegner et al, 2021) and when relying on a known-groups comparison (Roma et al, 2020) research paradigm; (d) the IOP-29 yields incremental validity when used in combination with other SVTs (Giromini et al, 2019) or PVTs (Giromini et al, 2020a); (e) the IOP-29 preserves its effectiveness also when used outside the USA, in countries such as Australia (Gegner et al, 2021), the UK (Winters et al, 2020), Italy (Giromini et al, 2018), Portugal (Giromini et al, 2020a), or Lithuania (Ilgunaite et al, 2020).…”